Skip to content

Effect of Dietary Intervention on LDL-C and Lipoprotein Subclasses Distribution in Patients With Hypercholesterolemia

Effect of Dietary Intervention on LDL-C Levels and Lipoprotein Subclasses Distribution in Patients With Hypercholesterolemia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04148976
Enrollment
62
Registered
2019-11-04
Start date
2013-02-28
Completion date
2018-12-18
Last updated
2019-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disease, Dyslipidemias, Hypercholesterolemia

Keywords

hypercholesterolemia, dietary portfolio, soy protein, LDL-C, lipoprotein subclasses, nopal, chia seed, functional foods

Brief summary

The primary aim of the present study was to elucidate the effect of a combination of functional foods on the low-density lipoprotein cholesterol (LDL-C) levels and on the distribution of the lipoprotein subclasses in subjects with hypercholesterolemia. To accomplish the latter, subjects that met the inclusion criteria and had mild hypercholesterolemia (Total cholesterol \>200mg/dL, and LDL-C \>130mg/dL \<190 mg/dL) were recruited for double-blind, parallel, controlled dietary intervention study. After two weeks of dietary standardization with an isocaloric diet, subjects were randomized and allocated to either placebo or a dietary portfolio treatment for two months. The secondary endpoints were the size of the different lipoprotein subclasses, total cholesterol levels, high density -lipoprotein cholesterol (HDL-C) levels, apolipoprotein B, triglycerides, total/HDL-C ratio, apolipoprotein B/apolipoprotein A ratio, and anthropometric measurements.

Detailed description

The present work took place at the Department of Physiology of Nutrition at the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (INCMNSZ). The study followed a randomized, controlled, double-blind, parallel design encompassing five visits. On the first visit, volunteers were screened for eligibility criteria. Subjects that met the inclusion criteria were then invited to a second visit. Herein, volunteers received a thorough explanation of the experimental maneuver, as well as the overall objectives of the study. Thereafter, subjects who agreed to participate signed a consent form. Upon agreement, assessment of habitual dietary intake and physical activity was obtained by 24-hour dietary recalls, food frequency questionnaire (FFQ), and by the International Physical Activity Questionnaire (IPAQ), respectively. Additionally, anthropometric measurements and blood samples were registered and collected. Then, volunteers underwent dietary standardization for two weeks with isocaloric diets (LSFD), which followed the National Cholesterol Education Program (NCEP) , Adult Treatment Panel III (ATP III) criteria. That is, 50-60% carbohydrates, 15% protein, 25-35% fat,\<7% saturated fat,≤ 200mg of dietary cholesterol, 20-35g of fiber, and 2000mg/d of sodium. On the third visit, subjects were randomly allocated to either LSFD plus placebo or an LSFD plus the dietary portfolio (DP). Of note, the prescribed diets were matched to the volunteers' habitual caloric intake -considering the energy provided by the placebo or DP- to avoid variability of the endpoint variables due to weight-loss. The DP and placebo provided 200kcal; the DP included 25g of soy protein, 14g of dehydrated nopal,14g of oats, 4g of chia seeds, 4g of inulin, and 0.15g of flavoring. The placebo consisted of 30g of calcium caseinate, 30g of maltodextrin, and 0.2g of flavoring. The organoleptic characteristics and packaging were similar between treatments. Subjects were instructed to consume two packets per day, preferably with breakfast and dinner. The content of each packet (30g of product) was dissolved in 250-300ml of water. Volunteers followed the given treatment for two consecutive months, during which two follow-up visits took place. Blood samples, anthropometric characteristics, and blood pressure were obtained in all visits. Compliance to diet, placebo, and DP was assessed with 24-hour dietary recalls, 3-day dietary records, and with the number of empty packets returned on the corresponding visits.

Interventions

DIETARY_SUPPLEMENTPlacebo

A mixture of maltodextrins and calcium caseinate divided into 30g individual packets.

DIETARY_SUPPLEMENTDietary portfolio

A mixture of functional foods divided into 30g individual packets.

Sponsors

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

The DP and placebo were packed in identical form and appearance. The treatment was provided in sealed boxes to the participants by an individual external to the study, but who performed the randomization. Furthermore, the researcher and the volunteer were unaware of the allocation of treatment.

Intervention model description

This study had two stages. In the first stage, subjects underwent dietary standardization with low saturated fat dietary treatments (LSFD) designed according to NCEP, ATP III criteria, and that provided the same amount of energy as that of the habitual diet of the volunteers, as assessed by 24-hour dietary recalls. In the second stage, subjects were randomly allocated to two different treatments, 1) LSFD plus placebo or, 2) LSFD plus dietary portfolio. Subjects were instructed to consume two packets of the corresponding treatment a day dissolved in 250-300 ml of water before breakfast and dinner for two consecutive months.

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Men and women * Body mass index (BMI) 25 to ≤ 39.9 kg/m2 * Adults between 20 and 60 years of age * Total cholesterol levels of \>200mg/dL in serum * LDL-C levels ≥130mg/dL ≤190mg/dL * Literate subjects * Signature of informed consent

Exclusion criteria

* Subjects with diabetes * Diseases that produce obesity or diabetes * Cardiovascular events * Weight-loss of ≥ 3kg on the preceding months to the study * Catabolic diseases such as cancer and acquired immunodeficiency syndrome * Pregnancy and breastfeeding * Positive Smoking * Pharmacological treatment including: Antihypertensive drugs Hypoglycemic agents Statins, fibrates or any other treatment for dyslipidemia Steroid medications Chemotherapy, immunosuppressants, and radiotherapy Anorexigens or other medication to induce weight-loss * Subjects with high cardiovascular risk * Subjects with symptomatic digestive pathologies

Design outcomes

Primary

MeasureTime frameDescription
Low density lipoprotein- cholesterol (LDL-C)Change in total LDL-C after 2.5 months of treatmentPlasma total LDL-C (mg/dl)
Lipoprotein subclassesChange in small, medium and large LDL, HDL and VLDL lipoprotein subclasses after 2.5 months of treatmentHigh density lipoprotein (HDL), low density lipoprotein (LDL), and very low density lipoprotein (VLDL) subclasses (small medium and large) as measure by nuclear magnetic resonance spectroscopy (NMR) in μmol/L.

Secondary

MeasureTime frameDescription
High density lipoprotein cholesterol (HDL-C)Change after 2.5 months of treatmentPlasma HDL cholesterol (mg/dL)
Apolipoprotein BChange after 2.5 months of treatmentChange in apolipoprotein B in
Total cholesterolChange in total cholesterol after 2.5 months of treatmentPlasma total cholesterol (mg/dL)
Total/ high density lipoprotein cholesterol (HDL-C) ratioChange after 2.5 months of treatmentChange in total/ high density lipoprotein cholesterol (HDL-C) ratio
Apolipoprotein B/Apolipoprotein A ratioChange after 2.5 months of treatmentChange in Apolipoprotein B / Apolipoprotein A ratio
Apolipoprotein AChange after 2.5 months of treatmentChange in apolipoprotein A in plasma
TriglyceridesChange in triglycerides after 2.5 months of treatmentPlasma triglycerides (mg/dL)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026